Pricing Log in Create free account
Saturday 17 October 2026 Export ENVB’s income statement to Excel — free account

Enveric Biosciences, Inc.

ENVB Healthcare Biotechnology

In the quarter to June 2026, EPS grew 93.5% and free cash flow fell 29.3%, each against the same quarter a year earlier.

1.38 0.01 −0.72%
Market cap
$6.2M
P/E
0.0×
Fwd P/E
−3.6×
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
−4.74
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 6.22
Revenue 35.41
Net Income (8.73)
Free Cash Flow (8.56)
Net Debt (8.30)
Current Ratio 10.21 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (3.57) (negative: loss-making)
P/S ratio 0.16
P/B ratio 0.68
Past 5Y EPS Growth —
This Y EPS Growth 38.66% (at or above 15%: strong)
Next Y EPS Growth 25.86% (at or above 15%: strong)
Next Y revenue growth (100.00%) (below 0%: weak)
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −0.1×, against a ten-year median of 5.8×; over the ten years it ranged from −0.1× in 2026 to 48,809,147× in 2016.
P/S against its own 10 years 14.07%
10-year low 10-year high
P/B against its own 10 years 10.69%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 2 2 5 8
Receivables — — — —
Inventory — — — —
Other — — — —
4 3 5 9
2023 2024 2025 Q'26
Payables 1 1 1 1
ST’ Debt — — — —
Other 0 0 — —
2 1 1 1

Compound Annual Growth %

10y 5y 3y
Sales — — 3.36%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 32.08% 4.11% (34.21%)

Revenue $m

Mar Jun Sep Dec Year
’26 11 11 9 — —
’18 11 11 11 10 43
’17 12 12 13 11 49
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) (2) — — —
’25 (2) (2) (2) (2) (8)
’24 (3) (3) (1) (1) (8)
’23 (5) (4) (3) (2) (14)
’22 (5) (5) (5) (3) (17)
’21 (3) (2) (2) (4) (11)
’20 (1) 0 0 (2) (4)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) (2) — — —
’25 (2) (2) (2) (2) (8)
’24 (3) (3) (1) (1) (8)
’23 (5) (4) (3) (2) (14)
’22 (5) (5) (5) (3) (18)
’21 (3) (2) (2) (4) (12)
’20 (1) 0 0 (2) (4)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (1.08) (0.76) — — —
’25 (14.65) (11.64) (10.81) 6.01 (36.24)
’24 (109.79) (45.00) (43.20) (30.22) (228.57)
’23 (415.76) (547.14) (233.98) (262.77) (1.46k)
’22 (989.90) (491.35) (262.77) (880.11) (2.34k)
’21 (1.80k) (382.95) (1.06k) (15.57k) (18.63k)
’20 (1.75k) (1.30k) (867.88) (6.82k) (10.71k)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 54,000,000.00 17,145,000.00 2,025,000.00 1,031,400.00 199,800.00 125,550.00 4,239.00 3,294.00 799.20 3.60

Analyst estimates 2026–2028

Powerpack
High 108,135,000.00 121,500,000.00 182,250,000.00 6,480,000.00 2,862,000.00 945,000.00 151,200.00 18,846.00 7,884.00 1,444.50
People
People Employees 237 417 390 397 3 24 26 7 6 6
Revenue/emp, $m 0.15 0.12 0.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Income, $m
Income, $m Revenue 36 49 43 — — — — — — —
Gross margin, % 19.17 21.07 20.89 20.42 0.00 0.00 0.00 — — —
EBT (7) (11) (11) (2) (7) (56) (20) (17) (10) (9)
EBT margin, % (18.05) (23.60) (24.53) 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net income (3) (9) (19) (2) (7) (49) (18) (17) (10) (9)
Depreciation 1 3 12 0 0 39 8 0 0 0
Per share, $
Per share, $ Revenue 2.77 3.24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings (0.21) (674,932.60) (737,926.40) (4,103.25) (10,708.93) (18,628.14) (2,339.77) (1,456.05) (228.57) (36.24)
Cash flow (0.21) (0.18) 0.00 (1,079.83) (6,481.33) (4,406.81) (2,143.34) (1,174.53) (184.39) (24.32)
Capex 0.00 0.00 0.00 (140.50) 0.00 (72.96) (73.02) 0.98 0.00 0.00
Free cash flow (0.21) (0.18) 0.00 (1,220.33) (6,481.33) (4,479.77) (2,216.36) (1,173.56) (184.39) (24.32)
Book value 0.89 1.30 0.00 (3,019.33) 5,692.67 8,579.19 1,833.99 163.03 38.01 12.48
Shares, m 13 15 0 0 0 0 0 0 0 0
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 — — — — — —
P/S 31,776,179.26 12,862,075.64 0.00 18.35 — — — — — —
P/B 98,504,220.80 32,144,241.44 0.00 0.00 — — — — — —
EV/Sales 31,776,179.74 12,862,075.69 0.12 18.47 — — — — — —
EV/FCF (420,244,075.32) (159,593,454.87) (1.09) (258.97) — — — — — —
Cash, $m
Cash, $m Operating cash flow (3) (3) (3) (1) (4) (11) (17) (14) (8) (8)
Capex 0 0 0 0 0 0 (1) 0 — —
Free cash flow (3) (3) (3) (1) (4) (12) (18) (14) (8) (8)
Balance, $m
Balance, $m Working capital (3) (16) (5) (2) 2 15 14 1 1 4
Total debt 19 7 5 1 — 0 0 — — —
Net debt 17 2 4 0 (2) (17) (18) (2) (2) (5)
Shareholders’ equity 12 19 11 (2) 3 22 15 2 2 4
Returns, %
Returns, % ROA (10.43) (24.35) (47.61) (16.21) (326.45) (317.87) (81.26) (146.39) (259.40) (296.67)
ROIC (11.63) (31.31) (30.60) 0.00 (191.11) (815.97) 0.00 0.00 0.00 0.00
ROE (46.66) (71.78) (129.02) (53.93) (875.21) (381.31) (101.68) (209.99) (539.57) (420.48)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2018 · latest quarter Sep 2019

Charts ten years each

Enveric Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ACXP Acurx Pharmaceuticals, Inc. $6.5M — (loss-making) — — n/m −2.36% (below 0%: shrinking) — 0.00% Compare
TCRT Alaunos Therapeutics, Inc. $6.4M — (loss-making) — (loss-making) +200.00% (above 0%: growing) n/m +57.20% (above 0%: growing) 100.00% 0.00% Compare
EVGN Evogene Ltd. $6.3M — (loss-making) — (loss-making) −35.02% (below 0%: shrinking) n/m +17.72% (above 0%: growing) 40.63% (738.62%) Compare
LEXX Lexaria Bioscience Corp. $6.3M — (loss-making) — (loss-making) −89.12% (below 0%: shrinking) n/m +53.90% (above 0%: growing) 100.00% 0.00% Compare
ENVB Enveric Biosciences, Inc. $6.2M — (loss-making) — (loss-making) −7.28% (below 0%: shrinking) n/m −29.34% (below 0%: shrinking) 0.00% 0.00%
TRAW Traws Pharma, Inc. $6.2M — (loss-making) — (loss-making) −100.00% (below 0%: shrinking) n/m −25.51% (below 0%: shrinking) 0.00% 0.00% Compare
ALZN Alzamend Neuro, Inc. $6.2M — (loss-making) — — n/m +51.82% (above 0%: growing) 0.00% 0.00% Compare
NRSN NeuroSense Therapeutics Ltd. $6.0M — (loss-making) — — n/m −23,458.82% (below 0%: shrinking) — 0.00% Compare
IMNN Imunon, Inc. $6.0M — (loss-making) — (loss-making) 0.00% n/m −4.24% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $6.3M — — −35.02% — +7.68% 20.32% 0.00%

All 614 Biotechnology stocks →

Enveric Biosciences, Inc. (ENVB) key facts

  • Enveric Biosciences, Inc. (ENVB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, ENVB traded at $1.38, a market capitalization of $6.2 million.
  • Return on equity was −420.5% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.

Enveric Biosciences, Inc. (ENVB) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/ENVB · Data as of Sep 30, 2019 · For information only; not investment advice. · © 2026 stockrow.com